To evaluate the efficacy and safety of ultrasound-guided percutaneous transhepatic microwave ablation in the treatment of liver cancer.

Methods:

Retrospective analysis of 35 cases (49 lesions) of primary or metastatic liver cancer treated by ultrasound- guided microwave ablation in Taicang First People's Hospital from Apr. 2015 to Jan. 2020

regular postoperative follow-up of contrast-enhanced ultrasonography (CEUS) and hepatic function (ALT) were performed to evaluate the therapeutic effect and liver injury

and to observe the complications.

Results:

All the lesions were completely inactivated by CEUS after operation. The results of follow-up showed that there was no recurrence in the liver at 3 months. There were 2 cases with recurrence of the original ablation site at 6 months

and no new cases at 9 months and 12 months. ALT increased significantly at 1 week after operation (

P

＜0.05)

and decreased to the same level at 1 month and 3 months after operation (

P

＞0.05). The complications of ablation included 1 case was stopped during operation due to pain

rest for 5 min; 15 cases had slight discomfort in incision or right upper abdomen; 23 cases had fever within 1 week after operation; 3 cases had small pleural effusion after operation; 1 case of postoperative abdominal hemorrhage.

Conclusion:

Ultrasound-guided percutaneous microwave ablation is a safe and effective method for the treatment of liver cancer. It is worthy of clinical application.